| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 64.5 | 54.3 |
| Gross profit | 38.3 | 28.0 |
| Profit before tax | -37.6 | -32.6 |
| Net income | -37.7 | -32.8 |
| EPS (diluted, $ a share) | $-0.50 | $-0.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +18.7% |
|---|---|
| Gross margin | 59.3% |
| Operating margin | -40.5% |
10-Q filed with the SEC, NASDAQ: SDGR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Schrodinger, Inc.: key numbers
- Share price
- $27.36Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Schrodinger, Inc.
All →Schrodinger Insider Robert Lorne Abel Sells $803K of Stock
Robert Lorne Abel sold 23,605 shares of Schrodinger, Inc. at $34.00 a share, worth $803K in total on Nov 11, 2026. Shares held after the trade: 54,219 (-3.0%).
- Value
- $803K
- Shares
- 23,605
- Average price
- $34.00
- Holding change
- -3.0%
- Trade date
- Nov 11, 2026
Schrodinger EVP, CLO & Cpo Yvonne Tran Sells $1.05M of Stock
Yvonne Tran, EVP, CLO & Cpo, sold 32,000 shares of Schrodinger, Inc. at $29.97 to $33.11 a share (average $32.85) in 4 transactions, worth $1.05M in total on Nov 9, 2026. Shares held after the trade: 52,683 (-29.1%).
- Value
- $1.05M
- Shares
- 32,000
- Average price
- $32.85
- Role
- EVP, CLO & Cpo
- Holding change
- -29.1%
- Trade date
- Nov 9, 2026
Schrodinger Financial Results
Schrodinger reported Q3 2026 financial results with total revenue of $64.5 million, a 19% increase year-over-year, driven by 17% growth in Annual Contract Value (ACV). The company raised its full-year 2026 guidance for both ACV and drug discovery revenue following strong software performance and a milestone payment from Structure Therapeutics.
- Term
- Q3 2026
“We are very pleased with our third quarter performance, delivering 17% ACV growth, $24 million of drug discovery revenue, and raising our full-year ACV and drug discovery revenue outlook. Our strong performance highlights the power of our industry-leading platform and also our business model in which our software and drug discovery businesses reinforce each other.”
Ramy Farid, Ph.D., chief executive officer of Schrödinger
Schrodinger Insider Karen Akinsanya Sells $928K of Stock
Karen Akinsanya sold 31,599 shares of Schrodinger, Inc. at $28.00 to $30.00 a share (average $29.37) in 2 transactions, worth $928K in total on Sep 17, 2026. Shares held after the trade: 69,956 (-23.6%).
- Value
- $928K
- Shares
- 31,599
- Average price
- $29.37
- Holding change
- -23.6%
- Trade date
- Sep 17, 2026